Asymchem Laboratories (Tianjin) Co., Ltd. and AUM Biosciences Pte. Ltd. announced a collaboration agreement. Under the terms of the agreement, AUM and Asymchem agree to collaborate on the process development, and the clinical and commercial production, of AUM 601, which is a highly selective oral small molecule inhibitor of the tropomyosin receptor kinase (TRK) for treating rare cancers.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
76.86 CNY | -0.59% | -1.98% | -33.80% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-33.80% | 3.71B | |
+25.44% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+13.06% | 233B | |
+5.35% | 201B | |
-9.90% | 193B | |
-12.26% | 143B | |
-6.47% | 144B |
- Stock Market
- Equities
- 002821 Stock
- News Asymchem Laboratories (Tianjin) Co., Ltd.
- AUM Biosciences Identifies Asymchem as the CDMO Partner of Choice for their Novel TRK inhibitor